Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Heitmann

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Annals of Hematology|January 19, 2022
Identification of CD105 (endoglin) as novel risk marker in CLLSarah M Greiner, Melanie Märklin, Samuel Holzmayer, et al.
Frontiers in Oncology|February 27, 2024
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)Susanne Jung, Richard F Schlenk, Christopher Hackenbruch, et al.
Journal of Leukocyte Biology|December 18, 2018
Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemiaDavid J Müller, Stefan Wirths, Alexander R Fuchs, et al.
Frontiers in Immunology|May 3, 2021
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue SarcomasIlona Hagelstein, Martina S Lutz, Moritz Schmidt, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2021
Platelet-expressed immune checkpoint regulator GITRL in breast cancerYanjun Zhou, Jonas S Heitmann, Kim L Clar, et al.
Frontiers in Oncology|October 29, 2024
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patientsSusanne Jung, Annika Nelde, Yacine Maringer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2023
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancersLatifa Zekri, Martina Lutz, Nisha Prakash, et al.
Frontiers in Oncology|September 10, 2024
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimensAlexander Englisch, Clara Hayn, Susanne Jung, et al.
European Journal of Immunology|August 23, 2021
SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector functionFabian Brunk, Andreas Moritz, Annika Nelde, et al.
Iscience|November 28, 2022
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunityAnnika Nelde, Jonas Rieth, Malte Roerden, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Annals of Hematology|January 19, 2022
Identification of CD105 (endoglin) as novel risk marker in CLLSarah M Greiner, Melanie Märklin, Samuel Holzmayer, et al.
Frontiers in Oncology|February 27, 2024
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)Susanne Jung, Richard F Schlenk, Christopher Hackenbruch, et al.
Journal of Leukocyte Biology|December 18, 2018
Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemiaDavid J Müller, Stefan Wirths, Alexander R Fuchs, et al.
Frontiers in Immunology|May 3, 2021
Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue SarcomasIlona Hagelstein, Martina S Lutz, Moritz Schmidt, et al.
Cancer Immunology, Immunotherapy : CII|February 4, 2021
Platelet-expressed immune checkpoint regulator GITRL in breast cancerYanjun Zhou, Jonas S Heitmann, Kim L Clar, et al.
Frontiers in Oncology|October 29, 2024
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patientsSusanne Jung, Annika Nelde, Yacine Maringer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2023
An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancersLatifa Zekri, Martina Lutz, Nisha Prakash, et al.
Frontiers in Oncology|September 10, 2024
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimensAlexander Englisch, Clara Hayn, Susanne Jung, et al.
European Journal of Immunology|August 23, 2021
SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector functionFabian Brunk, Andreas Moritz, Annika Nelde, et al.
Iscience|November 28, 2022
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunityAnnika Nelde, Jonas Rieth, Malte Roerden, et al.
Pageof 8